The end-of-phase 2 (EOP2) meeting with FDA is a critical milestone in your development program and likely the most important interaction you will have with the Agency. Getting the most from this meeting can help successfully launch your Phase 3 program and help you begin preparing for your marketing application (NDA/BLA) submission. If you are nearing completion of your phase 2 study or you are planning phase 3 programs, this webinar is built just for you.
This webinar covers:
Rho's dedicated regulatory strategy and submissions team is led by professionals with over 20 years of experience in clinical research, product development, data standards, quality assurance and regulatory affairs.